(TXG) 10X Genomics - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 3.006m USD | Total Return: 175.7% in 12m
Avg Turnover: 57.7M
Qual. Beats: 2
Rev. Trend: 79.8%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -6450.5 is critical
Altman Z'' -9.51 < 1.0 - financial distress zone
Choppy
Tailwinds
Leader, Tailwind, Pullback 52w, Confidence
10x Genomics, Inc. is a life sciences technology company that designs and manufactures integrated solutions for analyzing biological systems. Its core product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for in situ analysis. These systems combine proprietary hardware, specialized reagents, and data visualization software to map genetic information at high resolution.
The company operates within the high-growth multiomics sector, where researchers analyze multiple types of biological molecules simultaneously to understand disease progression. 10x Genomics utilizes a razor-and-blade business model, generating recurring revenue through the sale of proprietary consumables required to run its installed base of instruments. This model provides predictable cash flow as researchers scale their experiments across academic and biopharmaceutical institutions.
For a deeper look into the companys fundamental metrics, you may find it helpful to examine the detailed reports on ValueRay. 10x Genomics remains a key player in the transition from bulk genomic sequencing to spatial and single-cell resolution, serving as a critical infrastructure provider for modern drug discovery and clinical research.
- Customer budget constraints in academic and clinical research sectors slow instrument sales
- High-margin consumable recurring revenue growth stabilizes long-term cash flow profile
- Adoption of Xenium in situ platform drives market share in spatial biology
- Competitive pricing pressure from emerging single-cell sequencing startups impacts gross margins
- Intellectual property litigation costs and patent disputes create significant legal headwinds
| Net Income: -22.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 7.12 > 1.0 |
| NWC/Revenue: 87.06% < 20% (prev 75.53%; Δ 11.53% < -1%) |
| CFO/TA 0.13 > 3% & CFO 127.8m > Net Income -22.7m |
| Net Debt (-458.5m) to EBITDA (7.21m): -63.60 < 3 |
| Current Ratio: 5.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.3m) vs 12m ago 4.64% < -2% |
| Gross Margin: 69.60% > 18% (prev 0.68%; Δ 6.89k% > 0.5%) |
| Asset Turnover: 66.57% > 50% (prev 69.15%; Δ -2.58% > 0%) |
| Interest Coverage Ratio: -6.45k > 6 (EBITDA TTM 7.21m / Interest Expense TTM 6.00k) |
| A: 0.55 (Total Current Assets 669.7m - Total Current Liabilities 113.6m) / Total Assets 1.02b |
| B: -1.50 (Retained Earnings -1.52b / Total Assets 1.02b) |
| C: -0.04 (EBIT TTM -38.7m / Avg Total Assets 959.6m) |
| D: -7.57 (Book Value of Equity -1.52b / Total Liabilities 201.4m) |
| Altman-Z'' = -9.51 = D |
| DSRI: 1.04 (Receivables 56.1m/52.5m, Revenue 638.8m/624.7m) |
| GMI: 0.98 (GM 69.60% / 68.36%) |
| AQI: 2.71 (AQ_t 0.07 / AQ_t-1 0.02) |
| SGI: 1.02 (Revenue 638.8m / 624.7m) |
| TATA: -0.15 (NI -22.7m - CFO 127.8m) / TA 1.02b) |
| Beneish M = -2.13 (Cap -4..+1) = BB |
As of May 25, 2026, the stock is trading at USD 23.68 with a total of 3,735,950 shares traded.
Over the past week, the price has changed by +11.70%,
over one month by +7.25%,
over three months by +23.98% and
over the past year by +175.67%.
10X Genomics has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold TXG.
- StrongBuy: 5
- Buy: 2
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 25.2 | 6.5% |
P/E Forward = 400.0
P/S = 4.7063
P/B = 3.6887
Revenue TTM = 638.8m USD
EBIT TTM = -38.7m USD
EBITDA TTM = 7.21m USD
Long Term Debt = 70.1m USD (estimated: total debt 81.4m - short term 11.3m)
Short Term Debt = 11.3m USD (from shortTermDebt, last quarter)
Debt = 81.4m USD (from shortLongTermDebtTotal, last quarter) (leases 81.4m already included)
Net Debt = -458.5m USD (calculated: Debt 81.4m - CCE 539.8m)
Enterprise Value = 2.55b USD (3.01b + Debt 81.4m - CCE 539.8m)
Interest Coverage Ratio = -6.45k (Ebit TTM -38.7m / Interest Expense TTM 6.00k)
EV/FCF = 20.85x (Enterprise Value 2.55b / FCF TTM 122.2m)
FCF Yield = 4.80% (FCF TTM 122.2m / Enterprise Value 2.55b)
FCF Margin = 19.13% (FCF TTM 122.2m / Revenue TTM 638.8m)
Net Margin = -3.55% (Net Income TTM -22.7m / Revenue TTM 638.8m)
Gross Margin = 69.60% ((Revenue TTM 638.8m - Cost of Revenue TTM 194.2m) / Revenue TTM)
Gross Margin QoQ = 70.39% (prev 68.09%)
Tobins Q-Ratio = 2.51 (Enterprise Value 2.55b / Total Assets 1.02b)
Interest Expense / Debt = 0.01% (Interest Expense 6.00k / Debt 81.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -30.6m (EBIT -38.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.90 (Total Current Assets 669.7m / Total Current Liabilities 113.6m)
Debt / Equity = 0.10 (Debt 81.4m / totalStockholderEquity, last quarter 814.3m)
Debt / EBITDA = -63.60 (Net Debt -458.5m / EBITDA 7.21m)
Debt / FCF = -3.75 (Net Debt -458.5m / FCF TTM 122.2m)
Total Stockholder Equity = 792.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.36% (Net Income -22.7m / Total Assets 1.02b)
RoE = -0.98% (Net Income TTM -22.7m / Total Stockholder Equity 2.32b)
RoCE = -1.62% (EBIT -38.7m / Capital Employed (Equity 2.32b + L.T.Debt 70.1m))
RoIC = -8.18% (negative operating profit) (NOPAT -30.6m / Invested Capital 373.6m)
WACC = 12.59% (E(3.01b)/V(3.09b) * Re(12.93%) + D(81.4m)/V(3.09b) * Rd(0.01%) * (1-Tc(0.21)))
Discount Rate = 12.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 3.57%
[DCF] Terminal Value 65.52% ; FCFF base≈91.1m ; Y1≈104.4m ; Y5≈153.6m
[DCF] Fair Price = 15.19 (EV 1.32b - Net Debt -458.5m = Equity 1.77b / Shares 116.9m; r=12.59% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.79 | # QB: 2
Revenue Correlation: 79.83 | Revenue CAGR: 3.39% | SUE: 0.35 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.02 | Chg30d=+64.24% | Revisions=+33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.04 | Chg30d=N/A | Revisions=+0% | Analysts=3
EPS next Year (2027-12-31): EPS=0.20 | Chg30d=+19.98% | Revisions=+33% | GrowthEPS=+0.0% | GrowthRev=+8.8%
[Analyst] Revisions Ratio: +33%